Journal
NUCLEIC ACIDS RESEARCH
Volume 40, Issue 13, Pages 6380-6390Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nar/gks298
Keywords
-
Categories
Funding
- National Institutes of Health (NINDS) [5R21NS071023, AR049077, U54NS48843]
- NIH - NINDS [5R21NS071023]
- Direct For Mathematical & Physical Scien
- Division Of Chemistry [0840410] Funding Source: National Science Foundation
Ask authors/readers for more resources
The myotonic dystrophies (DM) are human diseases in which the accumulation of toxic RNA (CUG or CCUG) repeats in the cell causes sequestration of splicing factors, including MBNL1, leading to clinical symptoms such as muscle wasting and myotonia. We previously used Dynamic Combinatorial Chemistry to identify the first compounds known to inhibit (CUG)-MBNL1 binding in vitro. We now report transformation of those compounds into structures with activity in vivo. Introduction of a benzo[g]quinoline substructure previously unknown in the context of RNA recognition, as well as other modifications, provided several molecules with enhanced binding properties, including compounds with strong selectivity for CUG repeats over CAG repeats or CAG-CUG duplex RNA. Compounds readily penetrate cells, and improve luciferase activity in a mouse myoblast assay in which enzyme function is coupled to a release of nuclear CUG-RNA retention. Most importantly, two compounds are able to partially restore splicing in a mouse model of DM1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available